Role of SUMOylation in differential ERα transcriptional repression by SERMs and pure antiestrogens in breast cancer cells. Role of SUMOylation in differential ERα transcriptional repression by SERMs and pure antiestrogens in breast cancer cells

RNA-seq: Gene expression profiling in MCF-7 cells treated with vehicle (0), estradiol (E2), the Selective ER Modulator 4-hydroxytamoxifen (OHT), or the pure antiestrogen fulvestrant (ICI). ChIP-seq: Genome-wide DNA binding profile of ERα and SUMO2/3 in MCF-7 cells treated with vehicle, E2 or ICI. Overall design: RNA-seq: MCF-7 cells cultured in estrogen-depleted media were treated with vehicle, 5 nM E2, 100 nM OHT or 100 nM ICI for 16 h. Fold-Change of mRNA levels compared to vehicle was determined for each treatment condition (3 biological replicates for each). ChIP-seq: MCF-7 cells cultured in estrogen-depleted media were treated with vehicle, 5 nM E2 or 100 nM ICI for 30 min or 3 h. ChIP-seq with an antibody for ERα (Santa Cruz Biotechnology sc-543) was performed, and ERα peaks were called for each condition (3 biological replicates) relative to the corresponding input samples. MCF-7 cells cultured in estrogen-depleted media were treated with vehicle or 100 nM ICI for 30 min or 3 h. ChIP-seq with an antibody for SUMO2/3 (Cedarlane M114-3) was performed, and SUMO2/3 peaks were called for each condition (2 biological replicates) relative to the corresponding input samples.